Mirabegron for Overactive Bladder: A Novel, First-in-Class ?3- Agonist Therapy
Urology Journal,
Vol. 10 No. 3 (2013),
26 September 2013
,
Page 935-940
https://doi.org/10.22037/uj.v10i3.1640
Abstract
Purpose: To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-inclassnovel β3 receptor agonist drug recently approved by the food and drug administration
(FDA) for the treatment of overactive bladder (OAB).
Materials and Methods: We conducted a computerized search of the MEDLINE/PUBMED
databases with the word Mirabegron, β3 receptor agonist and overactive bladder.
Results: Effect of Mirabegron on β3 adrenergic receptor purportedly releases nitric oxide
(NO) by an increase in intracellular Ca2+ through accumulation of cyclic adenosine
monophosphate (cAMP). Along with NO which relaxes the detrusor muscle, it also
releases an urothelial-derived inhibiting factor (UDIF) that inhibits contractions. It increases
the bladder capacity by causing bladder relaxation during the storage phase.
Conclusion: Mirabegron appears to be a promising treatment in OAB patients by shifting
its management from reducing detrusor over-activity to inducing relaxation. Also it
lacks the troublesome side effects associated with the standard antimuscarinic management.
How to Cite
Imran, M., Najmi, A. K., & Tabrez, S. (2013). Mirabegron for Overactive Bladder: A Novel, First-in-Class ?3- Agonist Therapy. Urology Journal, 10(3), 935–940. https://doi.org/10.22037/uj.v10i3.1640
- Abstract Viewed: 368 times
- PDF Downloaded: 774 times